CA-125 Blood Testing and the Risk of a Delayed Ovarian Cancer Diagnosis

A CA-125 blood test can help evaluate a suspicious pelvic mass or monitor ovarian cancer treatment. It cannot, by itself, confirm that someone has ovarian cancer or establish that they are cancer-free.

That distinction matters when symptoms continue after a normal result. Persistent bloating, pelvic pain, difficulty eating, or urinary changes still need an appropriate explanation.

The question is whether the overall evaluation addressed those concerns, rather than whether one blood test fell within the laboratory’s reference range.

What the CA-125 Blood Test Measures

CA-125 stands for cancer antigen 125. It is a protein measured in the blood and used as a tumor marker, a substance that can provide information about cancer or the body’s response to it.

The protein is not exclusive to cancer. Noncancerous conditions and normal reproductive processes can also raise the amount circulating in the blood.

According to the National Library of Medicine’s explanation of CA-125 blood testing, a level above 35 units per milliliter, or U/mL, is commonly considered abnormal. Laboratory reference ranges and testing methods can vary, so the actual report matters.

The reference limit is not a dividing line between cancer and no cancer. A result above it requires interpretation, while a result below it does not exclude ovarian cancer.

Screening and Investigating Symptoms Are Different

Screening looks for disease before symptoms appear. Diagnostic evaluation investigates symptoms or another concerning finding.

The distinction changes how CA-125 should be used. The CDC’s explanation of ovarian cancer screening and diagnostic testing separates routine testing of people without symptoms from evaluation of unexplained symptoms. It also confirms that a Pap test does not screen for ovarian cancer. CDC

In its February 2018 recommendation, the U.S. Preventive Services Task Force recommended against ovarian cancer screening in asymptomatic women who are not known to have a high-risk hereditary cancer syndrome. This is a Grade D recommendation.

That recommendation does not tell clinicians to disregard symptoms. A person with persistent abdominal swelling or a suspicious ultrasound finding is facing a different clinical question from someone requesting a routine screening blood test.

For the same reason, not ordering CA-125 for an asymptomatic, average-risk patient does not, by itself, establish inappropriate care.

Why Screening Trials Did Not Establish a Survival Benefit

A screening test must do more than find abnormalities. Researchers need to determine whether using it reduces deaths and whether its benefits outweigh the harms of false alarms and unnecessary procedures.

The National Cancer Institute’s review of ovarian cancer screening evidence describes two major trials.

The PLCO trial evaluated annual CA-125 testing and transvaginal ultrasound in average-risk women. Screening did not reduce ovarian cancer mortality. False-positive findings also led some participants without cancer to undergo surgery.

The UKCTOCS trial evaluated ultrasound screening and a strategy that interpreted CA-125 changes over time, with ultrasound used in the assessment pathway. Long-term follow-up did not show a significant reduction in ovarian or tubal cancer deaths.

These results explain why routine population screening is not recommended. They do not establish that testing is unnecessary when symptoms or a concerning mass require investigation. NCI

When CA-125 Can Help Guide Care

The test has useful roles when its limitations are understood.

Clinical situation	What CA-125 can contribute	What it cannot establish alone
A suspicious pelvic or adnexal mass	Additional information to interpret alongside imaging, symptoms, and menopausal status	Whether the mass is definitely cancerous
Established ovarian cancer during treatment	A trend that may help assess response, particularly when the marker was elevated initially	Whether every area of cancer has responded
Follow-up after treatment	A change that may prompt assessment for recurrence	Whether chemotherapy should automatically begin
Persistent symptoms without a diagnosis	One part of a broader diagnostic evaluation	Reliable exclusion of ovarian cancer

An adnexal mass is a growth in the region of the ovaries, fallopian tubes, or nearby tissues. Its appearance and the patient’s clinical circumstances remain important even when CA-125 is normal.

Additional Risk Tests Have Specific Limits

Some assessment tools combine CA-125 with other information. For example, the Risk of Ovarian Malignancy Algorithm, or ROMA, combines CA-125, another marker called HE4, and menopausal status.

The FDA’s review of ROMA’s intended use describes its use in adults with an ovarian adnexal mass for which surgery is planned and who have not yet been referred to an oncologist. It must be interpreted with an independent clinical and imaging assessment.

ROMA is not intended for population screening, as a standalone cancer diagnosis, or to decide whether someone should undergo surgery. Adding another marker does not turn a blood test into definitive proof. accessdata.fda.gov

Persistent Symptoms Need a Follow-Up Plan

Symptoms associated with ovarian cancer include:

• Persistent bloating or increasing abdominal size.

• Pelvic or abdominal pain or pressure.

• Feeling full unusually quickly or having difficulty eating.

• Urinary urgency, increased urinary frequency, or other changes in bathroom habits.

These symptoms also occur with noncancerous conditions. Their presence does not diagnose ovarian cancer, but a continuing problem needs an appropriate assessment.

The CDC’s ovarian cancer symptom guidance advises seeing a doctor when these changes are unusual for you and last two weeks or longer. It advises prompt assessment for unusual vaginal bleeding. That two-week guidance is not a reason to postpone care for severe or rapidly worsening symptoms. CDC

Our guide to persistent bloating and early fullness explains how to describe these changes to a clinician.

A Normal Result Does Not Replace Hereditary Risk Assessment

CA-125 testing does not determine whether someone carries an inherited BRCA1 or BRCA2 variant or has another hereditary cancer syndrome.

The National Cancer Institute’s guidance on BRCA-related cancer risk explains that no effective ovarian cancer screening method is known, including for people with harmful BRCA variants. CA-125 and ultrasound have not been shown to detect these cancers early enough to improve long-term survival.

People with an inherited risk may need discussions about risk-reducing surgery and other management options. Those decisions involve the specific gene, age, reproductive plans, health, and consequences of treatment. A reassuring blood result does not replace that discussion.

Our explanation of germline and tumor BRCA testing describes why hereditary testing and cancer-focused testing answer different questions.

When Reliance on CA-125 May Raise a New York Malpractice Claim

A delayed diagnosis does not automatically establish malpractice. The review must address both whether care departed from accepted medical practice and whether that departure caused injury.

Potential concerns include treating a normal CA-125 as conclusive despite a suspicious mass, failing to investigate continuing symptoms appropriately, overlooking an imaging recommendation, or failing to complete an indicated specialist referral.

The relevant question is what the provider should reasonably have done with the information available at the time. A later cancer diagnosis does not prove that an earlier test should have detected it.

Causation requires a separate assessment. The claim concerns harm attributed to a missed opportunity for appropriate diagnosis or treatment. It does not assume that the clinician caused the underlying cancer.

Medical review may examine whether earlier investigation would have identified the disease and whether that would have changed treatment options or the likely course of illness. A later stage alone cannot establish the cancer’s exact stage at an earlier appointment.

Discussing a Normal CA-125 and a Later Ovarian Cancer Diagnosis

If a normal blood result ended the evaluation despite unresolved symptoms or concerning imaging, a legal review should examine what follow-up was indicated and whether an avoidable injury resulted.

Porter Law Group represents patients in New York cancer misdiagnosis and delayed-diagnosis matters. Our ovarian cancer malpractice lawyers can discuss your concerns and whether further review is appropriate.

Call 833-888-LATE, email info@porterlawteam.com, or request a free case evaluation. Continue medical evaluation and treatment while legal questions are considered.

This article is for informational and educational purposes only. It is not a substitute for medical advice from a qualified healthcare provider or legal advice based on your specific circumstances.

Attorney Advertising. Contacting Porter Law Group does not create an attorney-client relationship.

Frequently Asked Questions

Does a CA-125 above 35 mean I have ovarian cancer?

No. A result above the commonly used reference limit can occur with ovarian cancer, but it can also occur with endometriosis, fibroids, inflammation, pregnancy, and other conditions. Your clinician should interpret the actual value alongside your symptoms, medical history, and imaging. The result alone cannot establish a cancer diagnosis.

Can ovarian cancer be present when CA-125 is normal?

Yes. Some ovarian cancers do not cause an elevated CA-125, including some cancers found at an early stage. A normal result therefore cannot independently exclude the disease. If symptoms continue or imaging identifies a concerning mass, ask what further assessment or follow-up is appropriate for those findings.

Should everyone with persistent bloating have a CA-125 test?

No. Persistent bloating needs an appropriate clinical assessment, but there is no single test panel that every patient requires. History, examination, associated symptoms, and risk factors help determine whether CA-125, ultrasound, gastrointestinal evaluation, or another approach is indicated. The important question is whether the assessment adequately addresses the continuing problem.

Is CA-125 the same as BRCA genetic testing?

No. CA-125 measures a protein in the blood. Germline BRCA testing examines inherited DNA for variants associated with cancer risk. They answer different questions, even when both involve a blood sample. A normal CA-125 does not exclude an inherited risk, and a BRCA result does not diagnose a current ovarian tumor.

Can I bring a claim if my doctor relied on a normal CA-125?

Possibly, if the reliance departed from accepted care and caused injury. A review must consider the symptoms, examination, imaging, follow-up plan, and what earlier investigation could have changed. The normal result and later diagnosis alone do not prove malpractice. Filing deadlines should be assessed promptly while the medical timeline is reviewed.